RaySearch Laboratories (27R) Stock Overview
A medical technology company, provides software solutions for cancer treatment worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for 27R from our risk checks.
27R Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
RaySearch Laboratories AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 20.55 |
| 52 Week High | SEK 32.70 |
| 52 Week Low | SEK 13.00 |
| Beta | 1.01 |
| 1 Month Change | -4.86% |
| 3 Month Change | -28.27% |
| 1 Year Change | 58.08% |
| 3 Year Change | 295.19% |
| 5 Year Change | 182.67% |
| Change since IPO | 76.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| 27R | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | -4.6% | 0.7% | -1.6% |
| 1Y | 58.1% | 5.9% | 13.0% |
Return vs Industry: 27R exceeded the German Healthcare Services industry which returned 5.9% over the past year.
Return vs Market: 27R exceeded the German Market which returned 13% over the past year.
Price Volatility
| 27R volatility | |
|---|---|
| 27R Average Weekly Movement | 4.4% |
| Healthcare Services Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 12.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 27R has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 27R's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 431 | Johan Lof | www.raysearchlabs.com |
RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer treatment worldwide. The company offers RayStation, a treatment planning system for cancer centers; RayCare, an oncology information system for clinics; RayIntelligence, cloud-based oncology analytics system that cancer centers can use to gather, structure and analyze data; and RayCommand, a treatment control system designed to link the treatment machine and the treatment planning and oncology information systems. It also provides µ-RayStation* (Micro-RayStation), a software platform for planning and evaluation in small animal irradiation research; RayPlan, a treatment planning system; DrugLog, which verifies the identity and concentration of compounded injectables before administered to a patient; RayMigrate, allows users to convert Pinnacle patient data to RayStation format and/or to DICOM format; and machine learning and liver ablation solutions.
RaySearch Laboratories AB (publ) Fundamentals Summary
| 27R fundamental statistics | |
|---|---|
| Market cap | €701.19m |
| Earnings (TTM) | €17.62m |
| Revenue (TTM) | €114.37m |
Is 27R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 27R income statement (TTM) | |
|---|---|
| Revenue | SEK 1.25b |
| Cost of Revenue | SEK 107.02m |
| Gross Profit | SEK 1.15b |
| Other Expenses | SEK 952.56m |
| Earnings | SEK 192.95m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 07, 2025
| Earnings per share (EPS) | 5.63 |
| Gross Margin | 91.46% |
| Net Profit Margin | 15.41% |
| Debt/Equity Ratio | 0% |
How did 27R perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/03 15:09 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
RaySearch Laboratories AB (publ) is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Kristofer Liljeberg-Svensson | DNB Carnegie |
| Hans Mähler | Nordea Markets |